Acomplia - Lose weight, ease illness, quit smoking.
Posted on January 1, 2007
Sanofi-Aventis SA’s new treatment, Acomplia, also known as rimonabant, has shown promise in a half-dozen clinical trials in curbing the cravings that make people hungry and reach for a cigarette.
The experimental drug, which works differently from other weight-loss medicines, could be approved by the Food and Drug Administration as soon as this month. And industry analysts predict it could become the world’s first blockbuster antiobesity treatment, with annual sales of 2 billion to 4 billion euros, or $2.4 billion to $4.8 billion.
In studies, a 20-milligram dose once a day helped patients lose 5 percent to 10 percent of their weight in a year, raise good HDL cholesterol, lower triglycerides, and improve blood sugar and blood pressure.
» Filed Under Acomplia
Tags: Acomplia, rimonabant, Sanofi-Aventis
